U.S. FDA Panel Hears Risks with GlaxoSmithKline’s Advair, and AstraZeneca PLC’s Symbicort

ROCKVILLE, Md., Dec 10 (Reuters) - U.S. drug reviewers publicly clashed on Wednesday over how to handle a higher risk of death and serious complications seen with a class of asthma medicines now used by millions of patients including children.